Recursion Pharmaceuticals (NASDAQ:RXRX) used its latest earnings call to emphasize what management described as an inflection ...

Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) are trading higher Friday after the U.S. Food and Drug Administration announced plans to phase out its requirement for animal testing in favor ...

The biotech world is a prime target for risk-tolerant investors seeking out companies with the potential for dramatic gains. Firms in this space often either make it big—spiking upon news of a ...

Recursion's AI-enabled drug discovery platform continues to evolve, but this is yet to translate into meaningful clinical success. The recent cull of programs has further undermined investor ...

Advanced Micro Devices Inc. today announced that it has invested $20 million in Absci Corp., a company using artificial intelligence to develop new medicines. AMD will also partner with the company to ...

Initiated dosing of participants in the first-in-human study of ABS-101 (anti-TL1A antibody), with interim data expected in the second half of 2025 ABS-201 (anti-PRLR) non-human primate (NHP) data ...